Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of oral rilzabrutinib versus placebo in persistent or chronic immune thrombocytopenia
jRCT2051220003Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- May 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing Rilzabrutinib with Placebo (2 arms). Primary endpoints: Durable platelet response during the last 6 weeks of the 24-week blinded treatment period and EU and UK primary endpoint: platelet response in adult participants. Started May 2022; status: active, not recruiting.
02
Drugs
rilzabrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on jRCT2051220003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220003.